Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duloxetine - LAUNXP Biomedical

X
Drug Profile

Duloxetine - LAUNXP Biomedical

Alternative Names: Duloxetine hydrochloride - LAUNXP Biomedical; LXP-5268; LXPB-5268

Latest Information Update: 30 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LAUNXP Biomedical
  • Class Antidepressants; Antineoplastics; Anxiolytics; Naphthalenes; Non-opioid analgesics; Propanolamines; Small molecules; Thiophenes; Urologics
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Triple negative breast cancer

Most Recent Events

  • 25 Jul 2024 LAUNXP Biomedical plans clinical trials for Triple-negative-breast-cancer (PO)
  • 24 Jul 2024 Chemical structure information added
  • 18 Jul 2024 LAUNXP Biomedical has patent protection for duloxetine (LXP 5268) for the treatment of cancer in Taiwan, USA, Japan and Australia (LAUNXP Biomedical pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top